Discover if drinking 2 alcoholic beverages daily can damage your kidneys over time. Learn the science behind alcohol's impact ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Reductions in proteinuria have been shown to be importantly ... comparison with irbesartan in the primary endpoint of estimated glomerular filtration rate (eGFR) slope at 108 weeks.

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

BOSTON -- After living kidney donation, projection of renal function may vary by gender, a retrospective cohort study of ...

Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this ...

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...